

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31

March 24, 2022

DALLAS--(BUSINESS WIRE)--Mar. 24, 2022-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021, and host a corporate update conference call and webcast on Thursday, March 31, 2022, at 8:00 AM Eastern Time.

Conference Call Details

Thursday, March 31 at 8:00 AM Eastern Time / 7:00 AM Central Time

 Toll Free:
 877-407-0792

 International:
 201-689-8263

 Conference ID:
 13727816

 Webcast:
 https://ir.tavshaqtx.com/news-events/events-presentations

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goa of dramatically improving patients' lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005295/en/

Company Contact: Kimberly Lee, D.O. Chief Corporate Affairs Officer Taysha Gene Therapies klee@tayshagtx.com

Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies, Inc.